Monthly Archive for June 2010

Exposure to secondhand smoke in the womb has lifelong impact

Newborns of non-smoking moms exposed to secondhand smoke during pregnancy have genetic mutations that may affect long-term health, according to a University of Pittsburgh Graduate School of Public Health study published online in the Open Pediatric Medicine Journal. The abnormalities, which were indistinguishable from those found in newborns of mothers who were active smokers, may affect survival, birth weight and lifelong susceptibility to diseases like cancer.

The study confirms previous research in which study author Stephen G. Grant, Ph.D., associate professor of environmental and occupational health at Pitt’s Graduate School of Public Health, discovered evidence of abnormalities in the HPRT gene located on the X chromosome in cord blood from newborns of non-smokers exposed to environmental tobacco smoke.

In the current study, Dr. Grant confirmed smoke-induced mutation in another gene called glycophorin A, or GPA, that is representative of oncogenes – genes that transform normal cells into cancer cells and cause solid tumors. The GPA mutation was the same level and type in newborns of mothers who were active smokers and of non-smoking mothers exposed to tobacco smoke. Likewise, the mutations were discernable in newborns of women who had stopped smoking during their pregnancies, but who did not actively avoid secondhand smoke.

“These findings back up our previous conclusion that passive, or secondary, smoke causes permanent genetic damage in newborns that is very similar to the damage caused by active smoking,” said Dr. Grant. “By using a different assay, we were able to pick up a completely distinct yet equally important type of genetic mutation that is likely to persist throughout a child’s lifetime. Pregnant women should not only stop smoking, but be aware of their exposure to tobacco smoke from other family members, work and social situations.”

Literature: University of Pittsburgh Schools of the Health Sciences, Exposure to secondhand smoke in the womb has lifelong impact, June 30, 2010

Related Environmental Medicine Matters Articles:

Charge against the well known German Neurologist Dr. Binz

At June 15, the local press in Trier reported that the public prosecutor has brought a charge against the German neurologist Dr. Binz, who helped a lot of patients with work related illnesses. He is one of the few in environmental medicine who insist on their findings of toxic injuries. For that they treat him like the messenger who is to be shot.

1989, he won a case against a shoe manufacturer who poisoned his workers. This was the trigger for a long history of attempts to silence him. We already published the incidents in English. Please read the entire article.

Here is the time line:

  • 1989 Dr. Binz won a lawsuit in the second instance in Koblenz, which was lost in the first in Trier, against the shoe manufacturer Romika who had poisoned some of his workers.
  • 1993 a disciplinary action had been initiated with the allegation, he felt called upon to “pursue comprehensive investigations about the causes of certain disease syndromes”. The disciplinary action had been canceled but a reason for this was never stated. Mr. Spaetgens, a lawyer, just declared “it could have been”.
  • 1996 Dr. Binz had been subjected to accusations from the part of the German Berufsgenossenschaften (= BG, Workers Compensation).
  • 1997 an action had been brought before the Court of the Medical Profession (a special court of the Doctors’ Association concerned with professional conduct) at the Administration Court in Mainz by the state section of the Doctors Association.
  • 1997 he was prohibited to counsel his patients in matters of German social law.
  • 1998 there had been a new action before the Court of the Medical Profession, filed by the Doctors Association.
  • 1999 the Doctors Association repeated its action to have Dr. Binz’s license suspended. This was tried on accusations of false treatment and neglect of duty.
  • 2000 the Court for the Medical Professions decided to discontinue the lawsuit.

As usual, there is no debate on a substantial scientific level. But in the light of the eternally repeated psychogenic thesis, it would not be better for him.

Dr. Binz is charged with fraudulent billing of more than 2,800 patients. The German Association of Panel Doctors (Part of CHI) claims a damage of 100,000 Euros. The one who is known for standing up for his patients is alleged to have enriched himself.

The Story of Dr. Binz reflects the recognition state of environmental and work related illnesses caused by chemicals in Germany. Though Multiple Chemical Sensitivity is coded with T78.4 in the [German ICD-10]2 which became mandatory for billing in 2000, even patient friendly doctors refuse to diagnose MCS. Here’s a recent paper 3 from Australia which exemplifies how medical practitioners become outsiders (quacks) of their profession if they advocate MCS afflicted.

Dr. Binz didn’t dare to diagnose MCS. Recently on June 16, 2010 he admitted in a newspaper interview that he had no option for correct billing. In addition to the question of guilt the court should focus on the situation with the ICD-10. The question is not whether he cheated – the question is why doctors in Germany don’t dare to diagnose MCS according to the German ICD-10 and why health insurances don’t bear the costs if a doctor does. Why is it still possible in Germany to deny the existence of the ICD-code for MCS? (Use the iPhone app to look it up)

This is an international emergency call!

There is solidarity, but Dr. Binz needs more, so please take action!

Send a letter in your native language (they love it!)

  1. to the German Federal Ministry of Work, Social Affairs and Health,
  2. the executive board of the Panel Doctors Association or
  3. to the department of public prosecution

1) Ministerium für Arbeit, Soziales und Gesundheit
Postfach 3180
55021 Mainz
Bundesrepublik Deutschland

-
2) Vorstand der Kassenärztlichen Vereinigung
Rheinland-Pfalz
Postfach 2567
55015 Mainz
Bundesrepublik Deutschland

-
3) Staatsanwaltschaft
z. Hd. v. Dr. Jürgen Brauer
Irminenfreihof 10
54290 Trier
Bundesrepublik Deutschland

If you don’t want to write to German officials you may write to the press in Germany. You also can try to point your story to the press.

Here are some addresses for Germany:

taz
Rudi-Dutschke-Straße 23
10969 Berlin
Bundesrepublik Deutschland
email form: http://taz.de/6/kontakt/

-
der Freitag Mediengesellschaft mbh & Co. KG
Hegelplatz 1
10117 Berlin
Bundesrepublik Deutschland
email form: http://www.freitag.de/kontakt

-
Zeitverlag Gerd Bucerius GmbH & Co. KG
Pressehaus
Buceriusstraße, Eingang Speersort 1
20095 Hamburg
Bundesrepublik Deutschland
email: zeitiminternet(at)zeit.de

-

Frankfurter Rundschau
60266 Frankfurt am Main
Karl-Gerold-Platz 1
Bundesrepublik Deutschland
60594 Frankfurt am Main
mail: online(at)fr-online.de

-
Süddeutsche Zeitung GmbH
Hultschiner Straße 8
81677 München
Bundesrepublik Deutschland
email: redaktion(at)sueddeutsche.de

-

Reuters Deutschland
News-Center Berlin
Schiffbauerdamm 22
10117 Berlin
Bundesrepublik Deutschland

email form

Please twitter and post in facebook and on other places too.

-

Authors: BrunO Zacke, Silvia K. Müller, CSN – Chemical Sensitivity Network, 28. Juni 2010

Related Article: Mounting Actions against Environmental Medicine Practitioners

CFS Finally Recognized As ‘Medical Impairment’ Under Guidelines

Chronic Fatigue Syndrome a medically determinable impairment

One of the battles often fought by persons with CFS trying to obtain Social Security Disability Insurance and SSI benefits was resolved with the adoption of Social Security Ruling 99-2p. In this binding Ruling the Social Security Administration set out guidelines for adjudicators and judges to follow for claims based upon Chronic Fatigue Syndrome. This Ruling removes at least one of the barriers faced by Claimants.

What Was the Issue?

The Social Security Act allows for SSDI or SSI benefits to be paid to persons unable to work by reason of any medically determinable physical or mental impairment (or combination of impairments)….” (emphasis added) The Act and Regulations define the phrase “medically determinable” as a condition that can be established by medical evidence consisting of signs, symptoms and laboratory findings. It cannot be based only on the Claimant’s description of symptoms.

In claims based upon CFS there are obviously a lack of medical signs, symptoms and laboratory findings. Therefore many claims were denied on the failure to prove the existence of a “medically determinable impairment.”

What Does the Ruling Say?

The Ruling states unequivocally that CFS can be a medically determinable impairment. It specifies medical signs and laboratory findings that will now constitute proof of a medically determinable impairment for persons suffering from CFS. However, whether the Claimant is actually “totally disabled” is a separate determination based upon the severity of functional limitations caused by the disease. That is the same as in any claim based upon any other medical problem.

This Ruling requires that any of the following medical signs, which are clinically documented over a period of at least 6 consecutive months, can establish a medically determinable impairment:

  • palpably swollen or tender lymph nodes on physical examination;
  • nonexudative pharyngitis;
  • persistent, reproducible muscle tenderness on repeated examinations, including the presence of positive tender points; or,
  • other medical signs consistent with medically accepted clinical practice which are consistent with the other evidence in the case record.

The following laboratory findings can establish a medically determinable impairment for individuals with CFS:

  • an elevated antibody titer to Epstein-Barr virus capsid antigen equal to or greater than 1:5120, or early antigen equal to or great than 1:640;
  • an abnormal MRI brain scan;
  • neurally mediated hypotension as shown by tilt table testing or another clinically accepted form of testing; or,
  • other laboratory findings consistent with medically accepted clinical practice such as abnormal sleep studies and abnormal exercise stress tests that are consistent with other evidence in the case record.

Finally, mental impairments documented by mental status examinations or psychological testing can also establish the presence of a medically determinable impairment.

What Evidence Can Be Used to Show these Signs and Findings?

As in any claim for disability benefits the focus is upon the medical evidence, especially the clinical records and test results from treating sources. SSA will try to obtain all medical records, generally beginning 12-months prior to the month of application. The Ruling notes that conflicts in the medical evidence are not unusual in cases involving CFS and clarification should be sought first from the treating sources. Treating source opinions about the severity of the impairment should be given deference if they are well supported by medically acceptable clinical and laboratory techniques and are not inconsistent with other evidence in the records. It is noted that any information regarding functional abilities before and after the onset of the impairment is helpful in evaluating the claim. Finally third-party sources may be useful in determining the credibility of the Claimant.

As in any claim, the focus is upon a longitudinal view of all of the medical evidence. Claimants must be actively treating with medical providers and must be completely describing all symptoms each time they see the doctor. The doctors must keep careful, legible, notes during each visit so that the signs and findings noted above can be documented. In addition, the physician should be willing to provide a written opinion to SSA regarding the patient’s ability to sustain even sedentary work activity on an 8 hour per day, 5 days per week basis.

SSR 99-2p does not provide that every claim based upon CFS should be approved. It does, however, set forth guidelines for evaluation of these claims so that Claimants, physicians and representatives can be assured of a fair evaluation of the impairment and its impact on the individual.

Literature: Jeffrey A. Rabin & Assoc, CFS Finally Recognized As ‘Medical Impairment’ Under Guidelines, 24-7, June 26, 2010

Article provided by Jeffrey A. Rabin & Assoc, Visit at www.rabinsslaw.com

-

Related Articles:

CFS – Chronic Fatique Syndrome: FDA and NIH confirm ‘XMRV findings’

The FDA and the NIH have independently confirmed the XMRV findings as published in Science, October last. This confirmation was issued by Dr. Harvey Alter of the NIH during a closed workshop on blood transfusion held on May 26-27 in Zagreb. Two journalists from the Dutch magazine for health professionals, ORTHO, who have been working on XMRV stories for several months, were able to obtain a copy of the Alter lecture.

In the October 8, 2009 issue of Science Express, the Lombardi-Mikovits group at the Whittemore Peterson Institute (WPI), the Cleveland Clinic and the National Cancer Institute (NCI) reported that 67% of 101 chronic fatigue syndrome (CFS) patients tested positive for infection with xenotropic murine retrovirus (XMRV). Only 3.7% of 218 healthy subjects tested were positive for this gammaretrovirus. Since that time, a number of research groups have proved unable to independently confirm these findings.

On Friday last, the AABB released an Association Bulletin recommending that its member blood collectors actively discourage potential donors who have been diagnosed with CFS from donating blood or blood components. This interim measure was proposed by the AABB Interorganizational Task Force on XMRV. This Task Force includes representatives from several government agencies, including the Center for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

The fact that the measure was introduced suggests the presence of information not yet published. The ORTHO journalists were able to obtain a pdf document of the lecture given by Harvey Alter at the IPFA/PEI 17th Workshop on ‘Surveillance and screening of Blood Borne Pathogens’ in Zagreb. The International Plasma Fractionation Association (IPFA) represents the not-for-profit organizations around the world involved in plasma fractionation. The IPFA is based in Amsterdam, the Netherlands.

The highly-experienced Dr. Harvey Alter is Clinical Studies Chief at the Infectious Diseases and Immunogenetics Section of the Department of Transfusion Medicine at the NIH Clinical Center in Bethesda. “The data in the Lombardi, et al Science manuscript are extremely strong and likely true, despite the controversy”, was one comment on the XMRV findings reported by Alter in Zagreb. “Although blood transmission to humans has not been proved, it is probable. The association with CFS is very strong, but causality not proved. XMRV and related MLVs are in the donor supply with an early prevalence estimate of 3%-7%. We (FDA & NIH) have independently confirmed the Lombardi group findings.”

ORTHO contacted Dr. Harvey Alter today for a reaction. He did not want to comment, but confirmed that a paper is soon to be published.

Literature:

ORTHO, Dutch magazine for health professionals, FDA and NIH confirm ‘XMRV findings’, Gendringen, NL (MMD Newswire) June 22, 2010.

60 Scientists and NGOs Sound Joint Warning on Plastics Chemical

Scientists and NGOs concerned about the health impacts of bisphenol A

PRESS RELEASE, 23rd JUNE 2010

An unprecedented 60 scientists and international environment, health and women’s organisations from around the globe have jointly written to the European Food Safety Authority (EFSA) stating that

“action is necessary to reduce the levels of Bisphenol-A (BPA) exposure, particularly in groups at highest risk, namely young infants and pregnant mothers.”

[Quotes from some of the participating scientists and NGOs can be found towards the end of this release.]

In total, 41 NGOs and 19 scientists from 15 countries from across the globe (including 9 from the UK) have signed the letter. The letter comes on the eve of a new scientific opinion to be released by the EFSA on the safety of Bisphenol A in food contact materials expected in early July 2010. EFSA was requested by the European Commission to assess the latest science on Bisphenol A, and if necessary, to update the existing Tolerable Daily Intake (TDI) (a specific amount in food or drinking water that can be ingested (orally) over a lifetime without an appreciable health risk).

Bisphenol A is a mass produced chemical used in the manufacture of polycarbonate plastics that are clear and nearly shatter-proof. It can be found in plastics used for food and beverages, such as baby bottles, sports water bottles, as an epoxy resin in canned food and drinks, plastic food storage containers, tableware and in other products, including dental sealants, and has been found to leach into food and drink.

There have been long standing concerns about the health impacts of bisphenol A, due to scientific studies that have shown it has hormone disrupting effects at extremely low levels of exposure. Human bio-monitoring studies have shown that the vast majority of people in developed countries are exposed to Bisphenol-A.

EFSA’s previous opinions in 2007 and 2008 predominantly relied upon a handful of industry backed scientific papers that have expressed no concerns about our levels of BPA exposure. The letter from scientists and NGOs highlights scientific criticism in academic journals regarding these papers as compared to the “several hundred peer reviewed scientific papers have been published that have highlighted potential adverse health effects associated with BPA exposures”

The letter also draws attention to some of the new studies which have raised risks of exposure relating to a potential increased likelihood of developing ‘diabetes’, ‘developmental programming’ and ‘breast cancer’. Bisphenol A exposure at environmentally relevant levels commonly found in the environment in developed countries has also been repeatedly linked by independent university – based scientists to a number of other serious chronic health conditions.

Despite EFSA’s pivotal position in setting chemical food safety levels across the EU, Sweden and Germany have become the third and fourth most recent EU member states, alongside France and Denmark, to take action ahead of the EFSA review.

Andreas Carlgren, Sweden’s Environment Minister stated, on 11th May 2010, that

“If the EU will not quickly forbid the hormone disrupting substance bisphenol in baby-bottles Sweden will precede with a national prohibition.”

The President of the German Federal Environment Agency on the 9th June also broke from EFSA policy by issuing new guidance calling on

“manufacturers, importers and users of bisphenol A to use alternative substances that pose less risk to human health and the environment in all areas of use that significantly contribute to exposure”.

Regulators in Canada and the USA have already taken action to limit BPA exposure, for example in its use in baby bottles. As yet there has been no similar action at the European Union level.

A number of EU member states continue to back a common approach across the EU on bisphenol A. Tim Smith, the head of the UK Food Standards Agency, declared in an internal FSA report on the 12th May, 2010 that he ‘considers it important to have an agreed position across the EU’ and that the FSA will only ‘revise our position in line with it the EFSA Review if it is considered necessary’, despite the action that is being taken elsewhere across the EU.

The EFSA have already delayed publication of its review, as explained on its website:

To give the European Commission an up-to-date overview of the safety of BPA, EFSA will now deliver a scientific opinion in early July rather than end of May. This is due to the need for the Panel to consider hundreds of studies in its review and analysis of the most recent scientific literature.

The letter from scientists and organisations opens by ‘welcoming this announcement’ issued at the 11th hour that EFSA has finally agreed to examine hundreds of non-industry backed scientific papers.

The letter was drafted by Breast Cancer UK and Prof. Fredrick vom Saal, Curators Professor of Biological Sciences, University of Missouri-Columbia who has been awarded by his peers for his work on Bisphenol-A and is a recognised leader in this field. The effort was also coordinated by the Brussels based Health and Environment Alliance (HEAL).

Prof. vom Saal stated in response to the publication of the letter that:

“At the heart of the debate over BPA lies an outdated set of guidelines used by regulatory agencies that are based on approaches to evaluating the safety of chemicals established over 50 years ago. Thus, 21st century research approaches have provided overwhelming scientific evidence of harm in hundreds of published reports, but these findings are being rejected for consideration because they do not conform to the outdated testing guidelines.

“This has left regulatory agencies to rely entirely on industry-funded research that used ‘approved’ testing methods that are crude and insensitive, and it is not surprising that 100% of these industry-funded studies conclude that BPA causes no harm.

“The only rational path for European regulators is to take decisive action to reduce human exposure to BPA. The overwhelming nature of the total scientific evidence mandates this as a priority.”

Clare Dimmer, Chair of Trustees Breast Cancer UK and former breast cancer patient stated:

“Breast cancer is the most common cancer across Europe and has been increasing rapidly regardless of the costly and expensive efforts made by Governments to improve screening, treatment, and increase research. It must now be time that regulators act on the science and begin to take a precautionary approach to hazardous chemicals like bisphenol-A found in our everyday products.”

Lisette van Vliet, Ph.D. the Toxics Policy Advisor at HEAL said:

“It is high time that EFSA caught up to the overwhelming science showing genuine reasons for concern about our daily exposure to BPA.”

Participating scientists and organisations were given the opportunity to provide a quote for this press release; those that responded have been included below. This does not preclude participating organisations providing their own releases, supporting statements and additional comments.

Prof. Andrew Watterson, Occupational and Environmental Health Research Group, University of Stirling, said:

“It’s worrying, considering the weight of the scientific evidence, that strong action to reduce human exposure is yet to be taken. Hundreds of academic studies have explicitly raised the risks of developmental harm to foetuses and young children from exposure to BPA and this should dictate a strong precautionary policy response from European regulators. If this is not forthcoming, the UK Government must intervene as other European countries are already doing so.”

Daniela Hoffmann, Chemicals Expert, GLOBAL 2000/Friends of the Earth Austria:

“EFSA has to finally acknowledge the overwhelming scientific evidence concerning the risk BPA poses to human health.”

Sarah Häuser, Chemicals Expert BUND / Friends of the Earth Germany:

“The existing Tolerable Daily Intake for BPA does not protect human health. In animal experiments and biomonitoring studies, BPA doses much smaller than those estimated as being safe by EFSA were linked to chronic conditions health damages like diabetes and cardiovascular diseases. It’s time to take action now.”

For further information please contact:

Hratche Koundarjian, Campaign Manager, Breast Cancer UK, Charity No: 1088047, T: 07905 911 039, E: hratche@breastcanceruk.org.uk, W: www.breastcanceruk.org.uk / www.nomorebpa.org.uk

Letter and Signatories:

Prof. Klaus-Dieter Jany, Chair of the CEF Panel

European Food Safety Authority

Largo N. Palli 5/A, 43121 Parma, Italy

23rd June 2010

Dear Prof. Jany,

We are writing to welcome the announcement on the European Food Safety Authority (EFSA) website that the CEF panel will be considering ‘hundreds of studies in its review and analysis of the most recent scientific literature’ in its review of the TDI of bisphenol-A in food contact products.

Over the last decade and a half, a substantive body amounting to several hundred peer reviewed scientific papers, have been published that have highlighted potential adverse health effects associated with BPA exposures, at internal doses relevant to levels of biologically active BPA found in humans.

As a March 2010 Review (Vandenberg et al) of 80 bio-monitoring studies of BPA in Environmental Health Perspectives makes clear;

‘The two toxicokinetic studies performed to date, which suggest that human exposure is negligible, have significant flaws and are therefore not reliable for risk assessment purposes.’

However, in its prior risk assessments of BPA, EFSA only relied on a small number of studies rather than the much larger number that the United States Food and Drug Administration recently recognised as valid and of high utility in its risk assessment of BPA, and which led the FDA to express concern about the health hazards posed by BPA.

Only a tiny minority of studies have articulated that BPA exposure is completely safe, and many of these research papers have been criticised in academic commentaries and responses as having serious flaws, but it is these few flawed studies that EFSA previously relied on to declare BPA safe.

For example, a letter co-authored by 24 scientists published in the February 2010 edition of Toxicological Sciences states;

‘Publishing studies that conclude no harm in response to low doses of endocrine disrupting chemicals, when the studies did not include a positive control (Tyl et al., 2002), included inappropriate doses of positive controls (Ryan et al., 2009; Tyl et al., 2008), or included positive controls that showed no effect (Cagen et al., 1999), is inappropriate in peer-reviewed journals (Myers et al., 2009a,b; vom Saal and Welshons, 2006). Such studies violate basic principles of study design.’

Many scientific studies are now calling into question the safety of BPA. For example, a recent study has highlighted that BPA may contribute to metabolic disorders relevant to glucose homeostasis, and suggests that BPA may be a risk factor for diabetes (Alonso-Magdalena et al., 2010). Moreover, experiments at Yale university report that BPA may induce altered developmental programming (Bromer et al.,2010), and Doherty et al (2010) of Yale university have published a study which raises the concern about epigenetic effects of BPA on the regulation of the mammary gland, with potential implications for breast cancer risk. Endometriosis is also a concern as work by Signorile et al (2010) highlights that pre-natal exposure of mice to bisphenol-A causes an endometriosis-like response in female offspring.

It is therefore our opinion that any objective and comprehensive review of the scientific literature will lead to the conclusion that action is necessary to reduce the levels of BPA exposure, particularly in groups at highest risk, namely young infants and pregnant mothers.

There are an increasing number of countries that are either already committed to this course of action, or have signalled that they will soon be undertaking similar measures.

We share the concerns of these Governments and regulators and believe that reducing BPA exposure to these groups is both scientifically sound and in the best interest of public health.

As such, we call on you as the Chair of the CEF panel and the CEF Committee Members in their ongoing review to include all relevant studies, including bio-monitoring studies, and based on that evidence we conclude that there is a strong scientific mandate for action.

Yours sincerely,

  1. Benson Akingbemi, Associate Professor, Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, USA.
  2. Prof. Dr. Ibrahim Chahoud, Institute of Clinical Pharmacology and Toxicology, Dept. of Toxicology, Charité – Universitätsmedizin Berlin
  3. André Cicolella, Dipl Eng chemist-toxicologist.
  4. Prof. Patricia Hunt, Meyer Distinguished Professor, School of Molecular Biosciences, Washington State University
  5. Prof. Maricel V. Maffini. Ph.D. Research Assistant Professor. Department of Anatomy and Cellular Biology, Tufts University School of Medicine
  6. Jane Muncke, Ph.D, Environmental Toxicologist, Emhart Glass SA, Switzerland.
  7. John Peterson Myers, Ph.D., Chief Scientist, Environmental Health Sciences, Charlottesville VA.
  8. Angel Nadal, PhD, Professor of Physiology, Instituto de Bioingeniería and CIBERDEM, Universidad Miguel Hernández de Elche, Spain.
  9. Dr John Newby, Medical Information Scientist for the Cancer Prevention Society and Former Member of the Developmental Toxico-Pathology Research Group, Department of Human Anatomy & Cell Biology, Faculty of Medicine, University of Liverpool.
  10. Prof. Jörg Oehlmann, Goethe University Frankfurt am Main, Institute for Ecology, Evolution and Diversity.
  11. Prof. Gail S. Prins, PhD, Professor of Physiology, Department of Urology, University of Illinois at Chicago.
  12. Prof. Fredrick vom Saal, Curators Professor of Biological Sciences, University of Missouri-Columbia.
  13. Prof. Pietro Giulio Signorile, President of the Italian Endometriosis Foundation.
  14. Prof. Ana M Soto, MD, Department of Anatomy and Cell Biology, Tufts University, School of Medicine.
  15. Prof. Hugh S. Taylor, M.D., Professor of Molecular, Cellular and Developmental Biology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University.
  16. Laura N. Vandenberg, PhD, Postdoctoral Fellow, Center for Regenerative and Developmental Biology, Tufts University.
  17. Prof. Cheryl S. Watson, PhD, Professor, Biochemistry & Molecular Biology Dept. University of Texas, Medical Branch, Galveston.
  18. Prof. Andrew Watterson, Occupational and Environmental Health Research Group, University of Stirling.
  19. Prof. R. Thomas Zoeller, Biology Department, Morrill Science Center, University of Massachusetts.

-

  1. Action for Breast Cancer, Malta
  2. Alliance for Cancer Prevention, UK
  3. Arnika, Czech Republic
  4. Association for Environmental and Chronic Toxic Injury, Italy
  5. Austrian section of ISDE (International Society of Doctors for the Environment), Austria
  6. Breast Cancer Fund, USA
  7. Breast Cancer UK, UK
  8. BUND / Friends of the Earth Germany, Germany
  9. Cancer Prevention and Education Society, UK
  10. ChemSec –International Chemical Secretariat, International
  11. CHEM Trust, UK
  12. Chemical Sensitivity Network, Germany
  13. Clean Air Action Group, Hungary
  14. Comité pour le Développement Durable en Santé, France
  15. Danish Consumer Council, Denmark
  16. The Danish Ecological Council, Denmark
  17. Eco-Accord Program on Chemical Safety, Eastern Europe, Caucasus and Central Asia
  18. EcoAid, Germany
  19. Ecologistas en Acción, Spain
  20. Environmental Health Fund, USA
  21. Environment Illinois, USA
  22. European Environmental Bureau, EU
  23. Finnish Association for Nature Conservation, Finland
  24. Friends of the Earth Spain, Spain
  25. Global 2000 / Friends of the Earth Austria, Austria
  26. Health and Environmental Network, Europe
  27. Health Care Without Harm, International
  28. Indiana Toxics Action, USA
  29. Instituto Sindical de Trabajo Ambiente y Salud, Spain
  30. The Irish Doctors’ Environmental Association, Ireland
  31. Italian Endometriosis Foundation, Italy
  32. Plastic Planet, Austria
  33. Rachel’s Friends Breast Cancer Coalition, USA
  34. Réseau Environnement Santé, France
  35. Society for Sustainable Living, Czech Republic
  36. Unison, UK
  37. VHUE e.V., Germany
  38. Women in Europe for a Common Future, Europe
  39. Women’s Environmental Network, Scotland
  40. Women’s Voices for the Earth, USA
  41. WWF European Policy Office, Europe

-

References

German Translation by CSN:

60 Wissenschaftler und NGOs appellieren an EFSA